Table 3: Effects on lipid profile (X ± SD) in study patients.
|
Treatment |
Baseline |
12 weeks |
Changes (%) |
|
|
Low-density lipoprotein cholesterol (LDL-C) (mmol/L) |
||
|
Policosanol |
3.02 ± 0.76 |
2.55 ± 0.72*+++ |
-15.6+++ |
|
Placebo |
3.05 ± 0.81 |
3.26 ± 0.82 |
+0.8 |
|
|
Total cholesterol (mmol/L) |
||
|
Policosanol |
4.40 ± 0.79 |
4.04 ± 0.78*++ |
-8.4++ |
|
Placebo |
4.45 ± 0.90 |
4.75 ± 0.96 |
+7.4 |
|
|
High-density lipoprotein cholesterol (HDL-C) (mmol/L) |
||
|
Policosanol |
1.21 ± 0.39 |
1.29 ± 0.32*+ |
+6.6+ |
|
Placebo |
1.21 ± 0.39 |
1.20 ± 0.33 |
-0.8 |
|
|
Triglycerides (mmol/L) |
||
|
Policosanol |
0.89 ± 0.45 |
1.01 ± 0.57* |
+13.4 |
|
Placebo |
0.93 ± 0.42 |
1.11 ± 0.60* |
+19.4 |
X mean, SD standard deviation
*p < 0.05 Comparison with baseline (McNemar test)
+p < 0.05, ++p < 0.01, +++p<0.001 Comparison with placebo group (ANOVA)